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CLINICAL TRIALS AND OBSERVATIONS
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Additional chromosomal abnormalities
(ACAs) in Philadelphia-positive cells have
been reported in  5% of patients with
newly diagnosed chronic myeloid leuke-
mia (CML) in chronic phase (CP). Few
studies addressing the prognostic signifi-
cance of baseline ACAs in patients treated
with imatinib have been published previ-
ously. The European LeukemiaNet recom-
mendations suggest that the presence of
ACAs at diagnosis is a “warning” for
patients in early CP, but there is not much
information about their outcome after
therapy with tyrosine kinase inhibitors.
To investigate the role of ACAs in early
CP CML patients treated with imatinib
mesylate, we performed an analysis in a
large series of 559 patients enrolled in
3 prospective trials of the Gruppo Italiano
Malattie Ematologiche dell’Adulto Work-
ing Party on CML: 378 patients were evalu-
able and ACAs occurred in 21 patients
(5.6%). The overall cytogenetic and mo-
lecular response rates were significantly
lower and the time to response was signifi-
cantly longer in patients with ACAs. The
long-term outcome of patients with ACAs
was inferior, but the differences were not
significant. The prognostic significance
of each specific cytogenetic abnormality
was not assessable. Therefore, we con-
firm that ACAs constitute an adverse prog-
nostic factor in CML patients treated with
imatinib as frontline therapy. This study
was registered with clinicaltrials.gov as
NCT00514488 and NCT00510926. (Blood.
2012;120(4):761-767)
Introduction
Chronic myeloid leukemia (CML) is a clonal myeloproliferative
disorder characterized by the presence of the Philadelphia (Ph)
chromosome, produced by the reciprocal translocation t(9;22)(q34;
q11).1,2 This translocation leads to the generation of a chimeric
gene that results from the fusion of the ABL gene on chromosome 9
with the BCR gene on chromosome 22. The new leukemia-specific
fusion gene encodes a constitutionally activated protein tyrosine
kinases (PTKs) of different molecular weights (p185/190, p210,
and p230). The oncogenic PTK, located in the cytoplasm, is responsible
of the leukemic phenotype, through the constitutive activation of
multiple signaling pathways.3 At diagnosis, in most of cases the classic
t(9;22)(q34;q11) or its variant occur as the sole abnormality; additional
chromosomal abnormalities in Ph cells (ACAs) may appear in
 5% of cases, according to several series.4-6 The clinical impact of
these changes may be different depending on the treatment.
Almost 10 years ago, the CML therapy was radically changed
by the introduction of imatinib mesylate, a break point cluster-
Abelson (BCR-ABL)–targeting tyrosine kinase inhibitor (TKI).7-10
Despite the efficacy of imatinib in chronic phase (CP), treatment
failure or suboptimal response have been reported.11,12
The appearance of ACAs during treatment is commonly known
as clonal evolution (CE) and seems to play an important role in
imatinib mesylate resistance8; the emergence of ACAs during the
treatment is considered a poor prognostic feature. The World
Health Organization classification suggests that those patients
showing ACAs emerging during treatment should be considered in
accelerated phase (AP).13 The European LeukemiaNet recommen-
dations9,14 suggest that the presence of ACAs at diagnosis may
represent a “warning” feature, requiring careful monitoring of the
patient; however, the level of evidence at that time was low because
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few studies addressing the prognostic meaning of ACAs at
diagnosis, before starting imatinib treatment, have been published.
Conversely, ACAs emerging during the course of treatment are
considered a failure.
We report an analysis of Gruppo Italiano Malattie Ematologiche
dell’Adulto (GIMEMA) CML Working Party (WP), aiming to
clarify the impact of baseline ACAs on the response to the therapy
and on the outcome in newly diagnosed CML patients in early CP,
treated with imatinib as first-line therapy.
Methods
Patients
Patients (559) with previously untreated Ph and BCR-ABL–positive CML in
early CP were enrolled in 3 concurrent studies, promoted by GIMEMA
CML WP and opened to enrollment in 2004: CML/021 (NCT00514488), a
phase 2 trial exploring imatinib 800 mg in intermediate Sokal risk CP CML;
CML/022 (NCT00510926), a phase 3 trial comparing imatinib 400 versus
800 mg in high Sokal risk CP CML; and CML/023, an observational trial of
imatinib 400 mg in CP CML. The studies were approved by the Internal
Review Board of all participating institutions and performed according to
Good Clinical Practices and the Declaration of Helsinki.
Treatment monitoring and definition of response
Blood count and serum chemistry were performed at enrollment, monthly
until the 12th month of treatment and every 3 months thereafter. A complete
hematologic response (CHR) was defined as a white blood cell count of
 10  109/L, a platelet count of  450  109/L, no immature cells
(blasts, promyelocytes, and myelocytes) in the peripheral blood, and the
disappearance of all signs and symptoms related to leukemia (including
palpable splenomegaly).
All these study protocols required chromosome banding analysis and
fluorescence in situ hybridization (FISH) performed on bone marrow cells
at baseline, after 6 and 12 months of treatment, and every 6 months
thereafter or in case of failure or disease progression. Cytogenetic response
was established on at least 20 evaluable metaphases15; if  20 metaphases
were scored, FISH analysis was considered to confirm a complete
cytogenetic response (CCgR) when the rate of BCR-ABL–positive nuclei
was 1%.16
Real-time quantitative PCR was performed on peripheral blood and
bone marrow samples at baseline and after 3, 6, and 12 months and on
peripheral blood every 6 months thereafter. The molecular monitoring was
based on peripheral blood samples, and the molecular response was defined
as major (MMolR) if the BCR-ABL/ABL ratio was  0.10% on the
International Scale.17-19
Cytogenetics: chromosome banding analysis and FISH analysis
The GIMEMA CML WP has established a network of cytogenetic
laboratories covering all the country. Fourteen of these laboratories
performed cytogenetic studies for more than 1 clinical center (reference
laboratories), and 24 laboratories performed cytogenetic studies for
their respective clinical center (supplemental Table 1, available on the
Blood Web site; see the Supplemental Materials link at the top of the
online article). Chromosome banding analysis was performed on bone
marrow cells after short-term culture (24 hours, 48 hours, or both)
according to the International System for Human Cytogenetic Nomencla-
ture.20 A central review was not performed. At least 20 metaphases were
required.
The most frequent chromosomal abnormalities are defined as “major
route” abnormalities, and they include trisomy 8, duplication of Ph
chromosome, isochromosome 17q, and trisomy 19.21
FISH was performed on bone marrow cells prepared according to
cytogenetic techniques and by using DNA probes that hybridize at the BCR
and ABL regions.16-22 FISH analysis was performed on at least 200 cells.
Molecular studies
All samples and tests were centralized in Bologna, Italy. RNA extraction,
RT-PCR, and real-time quantitative PCR were performed according to
European recommendations, as described previously.23-25 Real-time
quantitative PCR was performed on an ABI PRISM 7900 sequence
detector (Applied Biosystems).19 ABL was used as the housekeeping
gene to correct differences in RNA quality, RT efficacy, or both. The
Table 1. Comparison of patients’ characteristics at diagnosis
Characteristic Patients with ACAs (N  21) Patients without ACAs (N  357) P
Median age, y (range) 45 (24-74) 50 (18-84) .18
Sex, male/female, N (%) 18/3 (86/14) 210/147 (59/41) .02
Median spleen, cm (range) 4 (0-21) 2 (0-23) .10
Median Hb level, g/dL (range) 11.8 (8.2-16.0) 12.0 (6.4-17.5) .77
Median PLT count, 109/L (range) 406 (143-979) 346 (107-4920) .79
Median peripheral blasts, % (range) 2.5 (1-8) 1 (0-10) .03
Median eosinophils, % (range) 3 (0-6) 2 (0-15) .53
Medin basophils, % (range) 2 (0-10) 2 (0-19) .82
Sokal score, N (%) .66
Low 7 (33) 140 (39)
Intermediate 6 (29) 134 (38)
High 8 (38) 83 (23)
Hasford score, N (%) .35
Low 6 (29) 159 (45)
Intermediate 13 (62) 173 (48)
High 2 (10) 25 (7)
EUTOS score, N (%) .20
Low 18 (86) 338 (95)
High 3 (14) 19 (5)
Variant Ph translocations, N (%) 1 (5) 24 (7) 1.00
Deletions der(9), N (%) 4 (19) 36 (10) .26
Imatinib dose (mg), N (%) .81
400 16 (76) 258 (72)
800 5 (24) 99 (28)
Hb indicates hemoglobin; PLTs, platelets; and EUTOS, European Treatment and Outcome Study.
762 LUATTI et al BLOOD, 26 JULY 2012  VOLUME 120, NUMBER 4
 For personal use only. by guest on September 8, 2013. bloodjournal.hematologylibrary.orgFrom 
results are expressed as ratio between BCR-ABL and ABL copies’
percentages. The BCR-ABL/ABL ratios percentages were further multi-
plied by the conversion factor of the Bologna laboratory to set the results
on an international scale.17-19
Definition of progression, failure, and events
The progression to advanced phases was identified by at least 1 of the
following criteria: peripheral blood myeloblast  10%; peripheral blood
myeloblasts and promyelocytes  30%; and any extramedullary blast
involvement, excluding spleen and liver. All the cases that did not meet any
of the above-mentioned criteria were defined as CP.
According to the international recommendations, failures were defined
as follows: no CHR at 3 months, no cytogenetic response (CgR) at
6 months, no partial CgR at 12 months, no CCgR at 18 months, loss of
CHR or CCgR previously achieved, new BCR-ABL mutation insensitive
to imatinib, and emergence of new ACAs or progression to the AP/blast
phase (BP).14,26
Events were defined as treatment failure or permanent discontinuation
of imatinib for any reason, including toxicity, patient refusal, or loss to
follow-up.
Statistical analysis
All comparisons between the 2 different groups of patients were assessed
with the Student t test and with Fisher exact test for categorical variables, as
appropriate. Times to CCgR and MMolR were calculated from the date of
start of treatment until the achievement of the first response. Overall
survival (OS), progression-free survival (PFS), failure-free survival (FFS),
and event-free survival (EFS) were calculated from the date of the first
imatinib dose until death (OS), until progression to AP or BP or death
(PFS), until failure or death (FFS), and until any event (EFS). Probabilities
of CCgR, MMolR, OS, PFS, FFS, and EFS were estimated using the
Kaplan-Meier method.27 Time to response and survival times were com-
pared with the log-rank test.28 All analysis were performed according to the
intention-to-treat principle. Multivariate logistic regression analysis was
used to assess the relationship between various predictors of interest and
response.
Results
Of the 559 patients enrolled into the GIMEMA CML WP studies
CML/021, CML/022, and CML/023 (see details in “Patients”),
378 (68%) had at least 20 evaluable metaphases at diagnosis and
were included in the present analysis and 181 had  20 evaluable
metaphases and were excluded from this study. In this way, we
have avoided the inclusion of eventual cases with a small clone
with ACAs in the group of cases without ACAs. However, no
excluded case showed ACAs.
In addition, 357 patients showed the presence of t(9;22)(q34;
q11) without additional abnormalities, and 21 patients (5.6%)
showed clonal ACAs.
Detailed baseline characteristics of the 2 groups are presented in
Table 1. The 2 groups, with and without ACAs, were similar for
demographic and hematologic characteristics except for sex and
percentage of peripheral blasts: the rate of male patients was
86% and 59% (P  .02) in patients with and without ACAs,
respectively; the median percentage of peripheral blasts was
2.5% and 1% (P  .03) in patients with and without ACAs,
respectively. The Sokal, Hasford, and European Treatment and
Outcome Study risk score distributions were comparable. The
Table 2. Cytogenetic details and treatment response of the 21 patients with clonal ACAs
Patient Sex Karyotype at diagnosis (% metaphases with ACAs) Der(9) deletion CgR 12m Outcome
1 Male 45,X,-Y,t(9;22)(q34;q11) (65) Yes CCgR CCgR
2 Male 45,X,-Y,t(9;22)(q34;q11) (100) No CCgR CCgR
3 Male 45,X,-Y,t(9;22)(q34;q11) (100) No CCgR CCgR
4 Male 45,X,-Y,t(9;22)(q34;q11) (100) No NoCgR Death
5 Male 45,X,-Y,t(9;22)(q34;q11) (100) No CCgR CCgR
6 Male 45,X,-Y,t(9;22)(q34;q11) (100) No NE Failure
7 Male 45,X,-Y,t(9;22)(q34;q11) (100) Yes PCgR CCgR
8 Male 45,X,-Y,t(9;22)(q34;q11) (33) No CCgR CCgR
9 Male 45,X,-Y,t(9;22)(q34;q11) (100) No PCgR CCgR
10 Male 47,XY,8,t(9;22)(q34;q11) (14) No mCgR Death
11 Male 47,XY,8,t(9;22)(q34;q11) (100) No PCgR Failure
12 Male 47,XY,8,t(9;22)(q34;q11) (100) No CCgR CCgR
13 Male 47,XY,t(9;22)(q34;q11),19 (100) No PCgR Drop-out
14 Male 47,XY,t(9;22)(q34;q11),19 (100) No CCgR Failure
15 Male 46,XY,t(9;22)(q34;q11),del(20)(q11q13) (100) Yes CCgR CCgR
16 Male 46,XY,del(7)(p21),t(9;22)(q34;q11) (100) No NE Failure
17 Female 46,XX,t(1;7)(p36;q31),t(9;22)(q34;q11) (100) No CCgR CCgR
18 Male 46,XY,t(6;11)(q13;q13)t(9;22)(q34;q11) (100) No CCgR CCgR
19 Female 46,XX,t(7;19)(q21;p13),t(9;22;22)(q34;q11;q11) (100) No CCgR CCgR
20 Male 46,XY,t(9;22)(q34;q11),t(X;13)(q13;q32) (100) Yes CCgR Failure
21 Female 46,XX,t(2;14)(p13;q32),der(14)t(2;14)(p13;q32), t(9;22)(q34;q11) (100) No NE Failure
PCgR indicates partial CgR; mCgR, minor CgR, NE, not evaluable; Failure, according to 2009 European LeukemiaNet criteria, described under “Definition of progression,
failure, abd events”; and Drop-out, imatinib permanent discontinuation for any reason different from failure.
Table 3. Response to imatinib (patients were categorized by their
response at the 12th month and by their best overall response)
Response
Patients with
ACAs, N  21 (%)
Patients without
ACAs, N  357 (%) P
CHR
Overall 21 (100) 350 (98) 1.00
CCgR
12th mo 12 (57) 267 (75) .12
Overall 15 (71) 317 (89) .03
MMolR
12th mo 10 (48) 205 (57) .50
Overall 14 (67) 306 (86) .03
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proportion of patients treated with high-dose imatinib was similar
in the 2 groups. No association of ACAs with variant Ph
translocations and with der(9) deletions was observed.
Cytogenetic analysis
In total, 21 CML cases with clonal ACAs were identified, and they
are described in Table 2. We observed loss of Y chromosome in
9 patients (43%; no. 1-9), trisomy 8 in 3 patients (14%; no. 10-12),
trisomy 19 in 2 patients (10%; no. 13 and 14), other different single
abnormalities in 6 patients (28%; no. 15-20), and complex karyo-
type with double ACAs in only 1 patient (5%; no.21).
Major route abnormalities (trisomies 8 and 19) occurred in 5 of
21 cases (24%).
One patient (no.19) showed a variant Ph chromosome: t(9;22;
22)(q34;q11;q11) that was characterized by chromosome banding
and FISH analysis.
Deletion of der(9) chromosome was detected by FISH analysis
in 4 cases (19%; no. 1, 7, 15, and 20): 2 cases with loss of
Y chromosome, 1 case with del(20)(q11q13), and 1 case with
t(X;13)(q13;q32).
In most patients, ACAs have been found in all the observed
cells; only 3 patients (no. 1, 8, and 10) had additional abnormalities
in a subclone (in 65%, 33%, and 14% of the metaphases,
respectively).
Response to imatinib mesylate therapy and survival
The median follow-up was 58 months (range, 25-75 months) and
60 months (range, 2-81 months) in patients with and without
ACAs, respectively. The response rates to imatinib are shown in
Table 3. The cytogenetic and molecular response rates were
uniformly lower in patients with ACAs: no significant differences
were observed at the 12th month, but the overall CCgR and
MMolR rates were significantly lower in patients with ACAs:
71% versus 89% (P  .03) and 67% versus 86% (P  .03),
respectively. The responses were significantly slower in the group
of patients with ACAs (Figure 1). In a multivariate logistic
regression, the presence of ACAs retained its prognostic signifi-
cance, when adjusted for other relevant variables (Table 4).
The median time to CCgR was 7 and 6 months in patients with
and without ACAs, respectively (P  .045). The median duration
of cytogenetic response has not been reached in both groups: 3 of
the 15 (20%) CCgR patients with ACAs and 27 of the 317 (8.5%)
CCgR patients without ACAs subsequently lost the previously
achieved CCgR; the estimated probability of survival without
cytogenetic relapse was 79% and 90% (P  .118) in patients with
and without ACAs, respectively. The median time to MMolR was
13 and 8 months in patients with and without ACAs, respectively
(P  .006). The long-term outcome is reported in Figure 2. The
estimated overall probabilities of EFS, FFS, PFS, and OS were
52% versus 68% (P .096), 61% versus 76% (P .062), 85% ver-
sus 89% (P  .453), and 89% versus 92% (P  .764) for patients
with and without clonal ACAs, respectively. Even if all outcomes
were inferior for patients with ACAs baseline, no difference versus
patients without ACAs baseline was statistically significant.
According to the type of cytogenetic abnormality, 9 cases
showed loss of Y chromosome, whereas in 5 cases a major route
abnormality (trisomy 8 and 19) was reported, in 6 cases a single
different abnormality was reported, and in the last case 2 ACAs
(Table 2) were reported: 7 of the 9 cases with loss of Y chromosome
(no. 1-9) retrieved and maintained a CCgR (6/7 MMolR either);
2 of 5 cases showing a major route abnormality obtained a CCgR
Figure 1. Cytogenetic and molecular response. Kaplan-Meier analysis; estimates of time to CCgR (A) and of time to MMolR (B). Dotted line indicates presence of ACAs, and
solid line indicates presence of only Ph chromosome.
Table 4. Multivariate logistic regression estimating the association between the presence of ACAs and the CCgR, considering other
covariates in the model
CCgR Odds ratio SE z P > z 95% confidence interval
ACAs 0.2506491 0.1418693 2.44 .014 0.082657-0.7600683
Variant Ph 0.5733353 0.3446664 0.93 .355 0.1764819-1.86259
del(9) 2.417083 1.554654 1.37 .170 0.6851781-8.526674
Sex 1.132707 0.3962182 0.36 .722 0.5706497-2.24836
Hemoglobin 1.3555 0.1237197 3.33 .001 1.133466-1.621029
Eosinophils 1.138051 0.100403 1.47 .143 0.9573391-1.352876
Basophils 0.9109481 0.488844 1.74 .082 0.8200029-1.01198
Imatinib dose 0.8333311 0.3054995 0.50 .619 0.4062251-1.709497
Sokal score 0.9955652 0.2284137 0.02 .985 0.6350055-1.560853
Variant Ph indicates variant Ph translocations; and del(9), deletion of derivative chromosome 9.
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by 12 months, but only 1 patient maintained the response with a
longer follow-up; 4 of the 6 cases with different single abnormalities
obtained and maintained either a CCgR and a MMolR (2/6 failed
imatinib); and 1 case with 2 ACAs (no. 21) discontinued imatinib
therapy because of treatment failure at 6 months. However, be-
cause of the small number of patients with ACAs, the different
prognostic significance of each specific cytogenetic abnormality
was not assessable.
Discussion
At diagnosis, the presence of clonal ACAs may be observed in
 5% of CP CML patients4-6; however, their appearance is mostly
associated with disease evolution and their frequency is higher in
late CP, AP ( 30%), and blast crisis ( 80%). The current
standard treatment approach for newly diagnosed CML patients is
based on TKIs, imatinib mesylate, the former standard of care, and
the second generation TKIs nilotinib and dasatinib, recently
registered as frontline treatments. There is much debate about the
“best” treatment strategy, between more or less conservative
approaches, considering imatinib or not as still a good option for
most patients as the frontline treatment. The prognostic signifi-
cance of the presence of clonal ACAs at diagnosis has been
discussed in previous studies, but data on the outcome of CP CML
patients with ACAs after therapy with frontline imatinib are
limited. The available studies are usually case reports, small series,
or large series but involving patients in different phases of disease,
more often in AP and/or treated with different drugs (eg, interferon
and TKIs).4,29-34 Reports suggested that, within different disease
stages, ACAs did not influence the response to therapy30,34; indeed
after second TKI therapy, the hematologic and cytogenetic re-
sponse rates, OS and EFS were no different between patients in CP
with CE and patients in CP without CE; but CE had a significant
impact when associated with other features of AP.34 These findings
are partially supported by a very recent study, in which only major
route ACAs were associated with a negative impact.35 On the other
hand, another observation reported that in early CP CML the
presence of ACAs was one of the independent adverse predictors
for PFS in the 6-months analysis and ACAs were present in 4 of the
6 patients who progressed within 1 year.7 The European Leukemi-
aNet recommendations provide a warning for CP CML patients
with ACAs treated frontline with imatinib, suggesting that ACAs
have impact on the outcome of CML,14 as they predict significantly
for shorter PFS and OS.7 The presence of ACAs has been
considered a feature of AP in some classifications of CML;
however, the World Health Organization classification suggested to
include ACAs as a criterion for AP only if they are not present at
diagnosis.13
In the present study, we report a large series of 559 early CP
CML patients treated with only imatinib as frontline therapy within
3 clinical trials of the GIMEMA WP on CML.
Clonal ACAs occurred in 21/378 evaluable patients (5.6%), a
frequency consistent with previous reports. We can confirm that
ACAs are not frequently detected in early CP of CML.
None of the cytogenetic abnormalities observed was considered
as constitutional, because of the type of abnormalities and/or the
fact that such abnormalities disappeared in all patients who
achieved a cytogenetic response. In our series the most frequent
observed abnormality was the loss of Y chromosome (43%). The
loss of Y chromosome is frequently associated with older age, and
might be in some cases only a consequence of ageing. However,
there are not univocal data on the significance of the loss of the
Y chromosome in CP-CML.4,35-38 We considered this abnormality
as ACA, differently from some other series published previously. In
our cases, the loss of Y chromosome disappeared in all patients
Figure 2. Long-term outcome. Kaplan-Meier analysis; estimates of EFS (A), FFS (B), PFS (C), and OS (D). Dotted line indicates presence of ACAs, and solid line indicates
presence of only Ph chromosome.
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who finally reached a CgR, confirming that the abnormality was
related to the hematologic disease.
The presenting features were substantially similar in the 2 groups
with and without ACAs (Table 1), except for sex and the median
percentage of peripheral blasts. The presence of ACAs seems more
common in male patients, as in our series the loss of Y chromosome
is the most frequent abnormality. As a matter of fact, the significant
unbalance in favor of males patients with ACAs disappeared
(P  .37) after exclusion of the 9 patients bearing the loss of
Y chromosome. The median percentage of peripheral blasts was
higher in the ACAs group: a slight difference most probably
deprived of biologic and clinical meanings. Deletions of a sizable
portion of the derivative chromosome 9 have been described in
10%-15% of CML patients and have been found more frequently in
patients with variant Ph translocations,39-40 but no association has
been described in patients with ACAs. However, a recent study41
asserted that deletions of der(9) do not influence the outcome of
CML in early CP patients treated with imatinib as frontline therapy.
In the present study, 4 of 21 patients (19% vs 10% without ACAs)
showed deletions of der(9) by FISH, but the difference was not
statistically significant.
Although the number of patients with clonal ACAs was
relatively low, the presence of ACAs influences the response to
imatinib therapy: the rates of CCgR and MMolR were significantly
inferior to those of patients with only Ph translocation (Table 3) and
the times to CCgR and MMolR were significantly longer in patients
with ACAs (Figure 1).
Previous studies have suggested that achievement of CCgR on
imatinib is a major prognostic factor for overall and progression
free survival,11-12 and that early molecular response is predictive of
long-term disease stability with lack of progression and durability
of CCgR.42-44
Furthermore, we observed a higher rate of response loss in the
patients with clonal ACAs, but the difference was not statistically
significant (data not shown). These differences in terms of re-
sponses, rate and rapidity, did not translate into different outcomes.
In fact, the number of negative events was higher in patients with
ACAs, but the corresponding EFS and FFS curves were not
significantly different (P  .09 and P  .06, respectively; Figure
2). Moreover, the survival without progression to AP/BP and
the OS probabilities were superimposable, and the higher
number of failures did not foresee a higher propensity to
progress, either for the low number of events overall or because
some of the patients who failed have been rescued to response
using second generation TKIs.
We were not able to investigate the differences concerning
response rate or survival related to the different kinds of abnormali-
ties, as we found only 3, 2, and 1 patient with trisomy 8, trisomy 19,
and 2 ACAs, respectively; moreover, 6 patients showed 6 different
single abnormalities that are not frequent in CML. However, our
data suggest a worse outcome in patients with major route
abnormalities (trisomy 8 and 19; Table 1, case no. 10-14), in
according to a recent report,35 even if we have not observed any
i(17q) and der(22q) in our patients, differently from their cases.
The only patient with complex karyotype, without major route
ACAs, failed the treatment and discontinued imatinib therapy. The
increased genomic instability may facility the emergence of a clone
with malignant phenotype.
In a recent paper, other authors reported that loss of Y
chromosome had a poor impact in patients in imatinib therapy, in
terms of cytogenetic and molecular response, EFS, and OS.38 Our
data, in agreement with a recent observation,35 do not suggest a
worse prognosis in 9 patients with loss of Y chromosome.
ACAs may be found in all the cells, or they may be acquired in a
subclone, thus defining a CE with worse outcome.30-31 In our series,
no correlation is possible, because only 3 patients (no. 1, 8, and 10;
Table 2) had abnormalities in a subclone: 2 patients with loss of
Y chromosome are still in CCgR and 1 patient with trisomy 8 died
in mCgR.
In conclusion, this large series of patients suggests that
ACAs at diagnosis, although not frequently detected, have a
negative impact in early CP CML patients treated with imatinib
as frontline therapy. Our data confirm that patients with ACAs
constitute a “warning” category, in terms of responses, and they
suggest that these cases could require a close monitoring and
treatment with second generation TKIs as frontline therapy. In
agreement with recent observations,35 more intensive therapy
should be considered in the patients showing major route
abnormalities and complex karyotype.
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